| 05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
| 03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
| 31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
| 30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
| 30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
| 03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
| 31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
| 05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
| Carolyn Cross |
156,314,029 |
£19,539,254 |
| Nicolas Loebel |
3,538,991 |
£442,374 |
| Junaid Bajwa |
1,193,697 |
£149,212 |
| Jean Duvall |
1,163,529 |
£145,441 |
| Jean Charest |
353,356 |
£44,170 |
| Carolyn Cross |
119,258,222 |
£14,907,278 |
| M&G Plc |
67,254,901 |
£8,406,863 |
| hInsight-NX, LLC |
42,272,654 |
£5,284,082 |
| Robert Cross |
37,772,652 |
£4,721,582 |
| Albemarle Life Sciences Fund |
15,105,882 |
£1,888,235 |
| CRUX Asset Management |
9,298,090 |
£1,162,261 |
| Chelverton Asset Management |
7,957,311 |
£994,664 |
| 17:08 |
40,000 @ 12.50p |
| 11:09 |
50,000 @ 12.28p |
| 09:59 |
40,000 @ 12.95p |
| Chair |
Jean Charest |
| CEO |
Carolyn Cross |
Top of Page
You are here:
research